Medicine may finally be catching up to their need
For the many people whose world tilts and spins without warning, vestibular migraine has long been a condition medicine acknowledged but could not adequately address. A new study suggests that gepants — oral and nasal medications that block a molecule woven through both the brain's pain and balance systems — may offer meaningful relief where other treatments have fallen short. Published in a leading otolaryngology journal and anchored in findings from the University of California, San Francisco, the research points toward a biological rationale that is as hopeful as it is overdue.
- Vestibular migraine silently devastates daily life for countless patients, yet it remains one of medicine's most underdiagnosed and undertreated conditions.
- The discovery that CGRP — the molecule gepants block — is active in the vestibular system as well as pain centers creates urgent new possibilities for targeting dizziness at its biological root.
- Patients using gepants both to abort acute attacks and prevent future ones reported universal benefit, with most finding relief within hours — a striking result in a field starved for effective options.
- The study's retrospective design limits its authority, and researchers are pressing toward larger prospective trials to transform promising signals into confirmed clinical guidance.
- In the meantime, the study's lead author has offered a measured but meaningful endorsement: gepants are reasonable to use now, a statement that carries real weight for patients who have waited years for an answer.
Vestibular migraine — the sudden, disorienting vertigo that can collapse entire days without warning — is the most common cause of recurring dizziness, yet medicine has long struggled to treat it well. A new study published in Otolaryngology–Head and Neck Surgery now suggests that gepants, a class of drugs already used for conventional migraine, may offer genuine relief.
Gepants work by blocking calcitonin gene-related peptide, or CGRP, a molecule long identified as central to migraine attacks. What gives this finding particular weight is that CGRP is also present throughout the vestibular system — the inner ear and brain structures that govern balance. That anatomical overlap provides a biological reason to believe these drugs could address dizziness itself, not merely headache pain.
The study examined patients who had used gepants — most commonly rimegepant, followed by ubrogepant — either during acute attacks, as daily prevention, or both. Those using them in both ways reported benefit in every case. Even patients treating only active episodes saw improvement nearly three-quarters of the time, with relief typically arriving within hours and lasting roughly a day. Three-quarters reported no side effects.
This stands in contrast to triptans, the standard abortive migraine treatment, which have never been shown to address vestibular symptoms specifically. Gepants also carry a practical advantage: they come as pills or nasal sprays rather than injections, lowering the barrier for patients who might otherwise avoid treatment.
Dr. Jeffrey D. Sharon of UCSF, the study's corresponding author, was careful to frame the findings as a beginning. The research was retrospective, and larger prospective trials are needed. Still, his conclusion was clear: gepants are reasonable to use for vestibular migraine now — a quiet but significant signal that medicine may finally be catching up to a condition that has gone undertreated for far too long.
Vestibular migraine—the spinning, the nausea, the sense that the room won't hold still—is the most common cause of recurring vertigo that strikes without warning. For people who live with it, the condition can flatten entire days, weeks, months. Yet it remains largely overlooked by medicine and undertreated by doctors who aren't sure what to do when a patient walks in dizzy and desperate. A new study published in Otolaryngology–Head and Neck Surgery suggests that a relatively new class of drugs called gepants may finally offer real relief.
Gepants work by blocking a molecule called calcitonin gene-related peptide, or CGRP, which researchers have identified as a key driver of migraine attacks. What makes this finding significant is that CGRP isn't just floating around in the brain's pain centers—it's also present throughout the vestibular system, the delicate network of structures in the inner ear and brain that keeps us balanced. This anatomical fact provides a biological explanation for something doctors have long suspected: that blocking CGRP might stop the spinning and dizziness, not just the headache.
The study looked at patients who had taken gepants—either as pills or nasal sprays—to treat vestibular migraine. The most popular choice was rimegepant, used by 88.2 percent of the patients studied, followed by ubrogepant at 58.8 percent. Some patients took the drugs only when an attack hit; others used them daily to prevent attacks from happening at all. The results were striking. Patients who used gepants both ways—to abort acute episodes and to prevent them—reported benefit in all cases. Even those who took them only when symptoms flared reported improvement 71.4 percent of the time. Most felt relief within hours, and the benefit typically lasted about a day. Three-quarters of patients reported no side effects at all.
This matters partly because the standard migraine drugs—triptans, which are among the most prescribed abortive medications—have never been shown to work specifically for the dizziness and vertigo of vestibular migraine, only for the headache. Gepants offer something different: a mechanism that addresses the underlying biology of the condition itself. They also offer something practical. Unlike CGRP monoclonal antibodies, which require injections, gepants come as pills or sprays. For patients who fear needles or simply prefer oral medication, this accessibility could be the difference between trying a treatment and avoiding it.
Dr. Jeffrey D. Sharon, the study's corresponding author at the University of California, San Francisco, emphasized that while these findings are encouraging, they represent a beginning, not an endpoint. The current study was retrospective—researchers looked back at patients who had already taken the drugs and reported their experiences. The next logical step is a larger, prospective trial in which patients are enrolled before treatment begins and followed systematically. "In the meantime," Sharon said, "we do think that it's reasonable to use gepants in the treatment of vestibular migraine." That measured endorsement carries weight. For patients who have endured years of spinning rooms and canceled plans, it signals that medicine may finally be catching up to their need.
Citações Notáveis
In the meantime, we do think that it's reasonable to use gepants in the treatment of vestibular migraine.— Dr. Jeffrey D. Sharon, University of California, San Francisco
A Conversa do Hearth Outra perspectiva sobre a história
Why has vestibular migraine been so hard to treat until now?
Because doctors didn't have a clear biological target. They knew triptans worked for headache pain, so they prescribed them for vertigo too, but the mechanism was never right. CGRP changes that—it's actually present in the balance system itself.
So gepants are different from the CGRP drugs people might already know about?
Yes. The monoclonal antibodies—those are injections you get monthly or quarterly. Gepants are pills or nasal sprays. Same target, completely different delivery. That matters more than it sounds.
The study showed 100 percent benefit when patients used them both ways. That seems almost too good to be true.
It's a small sample and retrospective, so you have to be careful. But the pattern is real: prevention plus acute treatment works better than either alone. That's true for most migraine therapies.
What happens to someone who gets relief within hours?
Their life changes. They can actually plan things. They're not trapped in bed for a day wondering if the room will stop spinning. That's not a small thing.
What's the next step for researchers?
A proper prospective trial—enroll patients, follow them forward, measure outcomes systematically. That's what will either confirm this or show where the limits are. But doctors aren't waiting. They're already prescribing these.